RXST — Rxsight Inc
NASDAQ · Healthcare · Medical Devices
$7.23
+$0.24 (+3.43%)
Rxsight Inc (RXST) is a medical devices company listed on NASDAQ. It is led by Ronald M. Kurtz M.D., based in 100 Columbia, Aliso Viejo, CA, United States, 92656, with about 461 employees. RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
Latest reported RXST revenue for 2025-09-30 was $30.3M. Net income was -$29.8M. Revenue was down 9.8% from 2025-06-30 to 2025-09-30. RXST currently screens at market cap $198.3M.
Use this RXST page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RXST quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RXST SEC filings page. Lician reads the product cache first so this HTML stays unique to Rxsight Inc even when a live quote feed is slow.
About Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Key Statistics
Market Cap
$198.29M
Volume
366,351
Previous Close
$6.26
Day Range
$6.14 – $6.41
P/B Ratio
0.74
EPS
-$0.71
Revenue
$139.93M
Net Income
-$27.45M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+57.1%
Profit Margin
-19.6%
Employees
461
RXST Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $139.93M | $89.08M | $49.01M | $22.59M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$27.45M | -$48.61M | -$66.76M | -$48.69M |
| EPS (Diluted) | -$0.71 | -$1.41 | -$2.41 | -$3.57 |
Total Assets
$318.56M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$16.71M
Operating Cash Flow
-$16.95M
Free Cash Flow
$0.00
Rxsight Inc Company Information
- President, CEO & Director
- Ronald M. Kurtz M.D.
- Headquarters
- 100 Columbia, Aliso Viejo, CA, United States, 92656
- Website
- rxsight.com
- Phone
- 949 521 7830
- IPO / Founded
- 2021-07-30
- Sector
- Healthcare
- Industry
- Medical Devices